Implantable Device May Lower Tough-to-Treat
TUESDAY, April 5 (HealthDay News) -- For people with
hard-to-control blood pressure, a new implantable device shows
promise, researchers report.
The device, surgically placed just below the collarbone, sends a
four- to six-volt electrical jolt to the carotid arteries. This is
said to lower blood pressure through a process known as baroreflex
The researchers were scheduled to present their findings Tuesday
at the annual meeting of the American College of Cardiology in New
"People with resistant hypertension -- high blood pressure that doesn't respond to multi-drug therapy and lifestyle changes -- are a growing group, and they're in desperate need of additional treatments," study lead author Dr. John D. Bisognano, professor of medicine in the cardiology division of the University of Rochester, said in a meeting news release.
"This system is safe, and its effect is as good as two or three drugs for people who are already taking five or six drugs and still can't control their hypertension," said Bisognano, who is also a consultant for CVRx, Inc., the device's maker, which funded the study.
The pulses generated by the device trick the body into thinking
that blood pressure has spiked. In response, the body sends out
regulators that cause blood pressure to fall, the researchers
explain in the news release.
For this phase 3 study (typically conducted before submitting a
device for approval by the U.S. Food and Drug Administration), the
device was implanted in 265 patients with high blood pressure
(readings over 160/80 mmHg) recruited from centers in the United
States and Europe. All of the patients had been taking three or
more blood pressure medications, including a diuretic, but their
hypertension remained uncontrolled.
Blood pressure readings higher than 140/90 mmHg increase the
risk of heart and kidney disease, stroke and death, experts
The patients were randomly assigned to one of two groups, with
both groups taking about the same number of medications. One group
received the baroreflex activation therapy device with activation
for the full 12 months. In the other group, the device was
programmed to start operating at six months.
The goal for systolic blood pressure (the top number in a blood
pressure reading) was under 140 mmHg. At monthly visits, if a
patient's target was not met, the voltage was upped to further
lower blood pressure.
Systolic blood pressure dropped in both groups, the researchers
reported. Forty-one percent of patients with the device achieved
target levels after six months, and more than half (54 percent) met
the goal after the 12-month mark.
The researchers were also surprised by a placebo effect noted in
the other group: about one-fifth of people who weren't getting
shocks still met their target for lowered blood pressure during the
first six months, or control phase, while 46 percent achieved the
target by the end of the study.
Overall, "reductions in [systolic blood pressure] at 12 months
were at least 50 percent of those seen at six months, demonstrating
a sustained response," the researchers wrote.
In both time periods, both groups saw their diastolic blood
pressure (the lower number in a reading) drop as well.
At the end of the study, "there was an 88 percent responder
rate, a 35 mmHg blood pressure drop and a decrease in left
ventricular mass," the researchers wrote, explaining that chronic
hypertension enlarges the heart's left ventricle.
"The data showed that the therapy significantly reduced blood pressure in patients with resistant hypertension," they said.
Cardiologists not involved in the study did offer some caveats,
Dr. Nieca Goldberg, director of the women's heart program at NYU
Langone Medical Center in New York City, called the treatment "a
novel approach" for people unable to tolerate or benefit from high
blood pressure drugs.
However, "this is more invasive than traditional ways to treat
hypertension, and there were only 265 participants in the study,"
she noted. "More research is necessary to see if there are gender
differences in treatment and if the benefit is there for a whole
range of people."
And although the device may effectively reduce blood pressure,
the surgery is risky, said Dr. Barry J. Materson, a professor of
medicine at the University of Miami Miller School of Medicine.
"In a study published in 2010, there were a number of serious adverse effects related to the surgery and the implanted device and wires," he said, but "no adverse effects are discussed in the present abstract."
Also, the study fails to address the costs associated with the
device, Materson said. "This needs to be weighed against the
long-term cost of the medications," he added.
Experts note that research presented at meetings is considered
preliminary until published in a peer-reviewed journal.
For more about high blood pressure, visit the
U.S. National Library of Medicine.
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.